


UnitedHealthcare Community Plan Pharmacy & Therapeutics Committee Tally

Meeting Date: September 14, 2023
 Location: Via conference call/Teams

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
Meeting called to order	G. Shutzberg		5:02 PM EST	
A. Minutes from previous meetings	G. Shutzberg	Review of Minutes from June 8, 2023	Minutes reviewed, approved	Yes
B. Conflict of Interest Training	S. Washington	Confirm Review of Conflict of Interest Training	COI reviewed, completed	Yes
C. Mental Health Parity Training	B. Wombles	Confirm Review of Mental Health Parity Training	MHP reviewed, completed	Yes
D. Formulary Review - New Drugs	M. Reisman	Airsupra Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
	M. Reisman	Breyana Recommendation: • Preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
	M. Reisman	Joenja Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
	C. Blosser	Daybue Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
	C. Blosser	Filspari Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
	C. Blosser	Lumryz Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
	M. Reisman	Paxlovid Recommendation: • Preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
	M. Reisman	Skyclarys Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
	M. Reisman	Uzedly Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
	M. Reisman	Abilify Asimtufii Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
	C. Blosser	Veozah Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
	C. Blosser	Vowst Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
	Comment:	Dr. Fitzhugh asked how does Veozah efficacy compare to that of SSRIs? There have not been comparison trials to date to compare it to the other treatment options. According to consultants, Veozah did seem to be more effective than SSRIs and SNRIs with reducing VMS symptoms. However it is difficult to compare the two of them because a study has not been conducted to evaluate the difference in efficacy between the therapies.		
	C. Blosser	Zavzpret Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
E. Formulary Review - PDL Modifications	C. Blosser	Confirm Review of PDL Modifications Grid	Yes/No	Yes
		Basaglar (insulin glargine) pen Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
		Insulin Glargine-yfqn (Semglee AG) vial and pen Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
		Rezvoglar pen Recommendation: • Preferred for NY EPP only	Motion made, seconded, and carried to accept recommendation	7:0
		Lantus vial Recommendation: • Preferred for NY EPP only	Motion made, seconded, and carried to accept recommendation	7:0
		Lantus Solostar Recommendation: • Preferred for NY EPP only	Motion made, seconded, and carried to accept recommendation	7:0
		Insulin Lispro Jr. Kwikpen (Humalog AG) Recommendation: • Preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
		Insulin Lispro Kwikpen (Humalog AG) Recommendation: • Preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
		Insulin Lispro Protamine/Insulin Lispro Kwikpen 75-25 (Humalog Mix AG) Recommendation: • Preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
		Humalog Mix 75-25 Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
		Admelog vial Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
		Admelog Solostar Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
		Insulin Lispro (Humalog AG) vial Recommendation: • Preferred for NY EPP only	Motion made, seconded, and carried to accept recommendation	7:0
		Insulin Lispro Jr Kwikpen (Humalog AG) Recommendation: • Preferred for NY EPP only	Motion made, seconded, and carried to accept recommendation	7:0
		Insulin Lispro Kwikpen (Humalog AG) Recommendation: • Preferred for NY EPP only	Motion made, seconded, and carried to accept recommendation	7:0
		Insulin Lispro Protamine/Insulin Lispro Kwikpen 75-25 (Humalog Mix AG) Recommendation: • Preferred for NY EPP only	Motion made, seconded, and carried to accept recommendation	7:0
		Humalog Jr Kwikpen Recommendation: • Preferred for NY EPP only	Motion made, seconded, and carried to accept recommendation	7:0
		Humalog Kwikpen Recommendation: • Preferred for NY EPP only	Motion made, seconded, and carried to accept recommendation	7:0

		<p>Victoza (three-pack)</p> <p>Recommendation: • Preferred with prior authorization across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Rybelsus</p> <p>Recommendation: • Preferred with prior authorization across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Ozempic</p> <p>Recommendation: • Preferred with prior authorization across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Mounjaro</p> <p>Recommendation: • Preferred with prior authorization across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Trulicity</p> <p>Recommendation: • Non-preferred with prior authorization across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Victoza (two-pack and three-pack)</p> <p>Recommendation: • Preferred with prior authorization for NY EPP only</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Mounjaro</p> <p>Recommendation: • Preferred with prior authorization for NY EPP only</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Ozempic</p> <p>Recommendation: • Preferred with prior authorization for NY EPP only</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Rybelsus</p> <p>Recommendation: • Preferred with prior authorization for NY EPP only</p>	Motion made, seconded, and carried to accept recommendation	7:0
	M. Reisman	<p>Recommendation: • Amphetamine and Methylphenidate-based stimulants (amphetamine/dextroamphetamine salts (generic Adderall), amphetamine/dextroamphetamine salts extended-release (generic Adderall XR), dextroamphetamine IR tablet (generic Dexedrine), dextroamphetamine extended-release capsule 24 HR (generic Dexedrine Spansule), dexamethylphenidate IR tab (generic Focalin), dexamethylphenidate ER capsule (generic Focalin XR), methylphenidate ER tablet (generic Concerta), generic Ritalin LA 20mg, 30mg, 40mg), methylphenidate SR (generic Metadate ER), methylphenidate (generic Ritalin), methylphenidate CD (generic Metadate CD): Move to preferred for members under 18 across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Lisdexamfetamine capsules (generic Vyvanse): Move to preferred with prior authorization for all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Lisdexamfetamine chewable tablets (generic Vyvanse): Move to non-preferred with prior authorization across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Colchicine oral tablet (generic Colcrys): Move to preferred across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Mitigare oral capsule: Move to non-preferred with prior authorization across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Ranolazine ER oral tablet (generic Ranexa): Move to preferred across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Fenofibrate Micronized oral capsule (generic Tricor) 67mg, 134mg, 200mg: Move to preferred across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
	M. Reisman	<p>Recommendation: • Fenofibrate oral tablet (generic Tricor) 54mg, 145mg, 160mg: Move to preferred across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Fenofibrate 48mg oral tablet (generic Tricor): Move to preferred across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Norethindrone-ethinyl estradiol FE 1 mg-20 mcg oral tablet (Blisolvi 24 FE, Hailey 24 FE, Larin 24 FE, Junel Fe 24, Aurovela 24 FE, Microgestin 24 FE, Tarina 24 FE): Move to preferred across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Norethindrone-ethinyl estradiol FE 1mg- 20mcg chewable tablet (Charlotte 24 FE, Mibelas 24 FE, Finzala) (generic Minastrin 24 FE): Move to preferred across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Norgestimate-ethinyl estradiol 0.18-25/0.215-25/0.25-25 mg-mcg oral tablet (Tri-Lo-Estarylla, Tri-Lo-Marzia, Tri-Vylibra LO) (generic Ortho Tri Cyclen Lo): Move to preferred across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Drospirenone-ethinyl estradiol 3-0.03 mg oral tablet (Ocella, Syeda, Zarah, Zumandimine) (generic Yasmin 28): Move to preferred across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Drospirenone-ethinyl estradiol 3-0.02 mg oral tablet (Jasmiel, Loryna, Nikki, Vestura, Lo-Zumandimine) (generic Yaz): Move to preferred across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Levonorgestrel-ethinyl estradiol 0.15-0.03mg (84) & ethinyl estradiol 0.01mg (7) oral tablet (Jamiesse, Ashlyna, Daysee, Simpesse, Camrese, Amethia) (generic Seasonique): Move to preferred across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Levonorgestrel-ethinyl estradiol 0.1-0.02mg (84) & ethinyl estradiol 0.01mg (7) oral tablet (Camrese LO, LoJamiesse) (generic LoSeasonique): Move to preferred across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Norethindrone-ethinyl estradiol FE 0.4 mg-35 mcg chewable tablet (Wymzya FE): Move to preferred across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Amoxicillin 500mg oral tablet: Move to preferred across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Cefpodoxime oral tablet: Move to preferred across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Calcium acetate oral capsule (generic PhosLo): Move to preferred across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Metoprolol Tartrate oral tablet (37.5mg, 75mg): Move to preferred across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Saxagliptin oral tablet (generic Onglyza): Move to preferred across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Nitro-Dur transdermal patch: Move to non-preferred with prior authorization across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0
		<p>Recommendation: • Cephalexin 750mg oral capsule: Move to non-preferred with prior authorization across all applicable lines of business</p>	Motion made, seconded, and carried to accept recommendation	7:0

F. Formulary Review - PDL Modifications Medical	M. Reisman	Confirm Review of PDL Modifications Grid	Yes/No	Yes
		Recommendation: • Somatuline injection: Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • Lanreotide injection: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • Zixtenzo injection: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • Udenyca injection: Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
G. Formulary Review - New Drugs- Medical	M. Reisman	Confirm Review of New Drugs- Medical Grid	Yes/No	Yes
		Adstiladrin Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
		Lamzede Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
		Syfovre Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
		Rezzayo Recommendation: • Medical benefit across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
		Zynyz Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
		Qalsody Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	7:0
H. Formulary Review - Drugs Evaluated Per Grid	C. Blosser	Apply recommendations as outlined in grid	Motion made, seconded, and carried to accept recommendation	7:0
I. Clinical Guidelines	C. Blosser	Clinical Guideline Review		
		Apply New Pharmacy Guidelines	Motion made, seconded, and carried to accept recommendation	7:0
		Continue to Apply Pharmacy Guidelines Requiring Modifications	Motion made, seconded, and carried to accept recommendation	7:0
		Remove Pharmacy Guidelines Requiring Archival	Motion made, seconded, and carried to accept recommendation	7:0
J. Quality Monitoring	A. Cline/ C. Blosser	Confirm Review of Quality Data	Yes/No	Yes
	A. Cline	DUR Review		
	C. Blosser	Drug Recalls – 2nd Quarter 2023		
	C. Blosser	Top 25 Drugs by Spend and Volume – 2nd Quarter 2023		
	C. Blosser	Top 10 Drugs Requested - Approvals and Denials – 2nd Quarter 2023		
	C. Blosser	Grievances and Appeals Data – 2nd Quarter 2023		
	C. Blosser	Inter-Rater Reliability (IRR) – 2nd Quarter 2023 • Pharmacists		
Adjournment	G. Shutzberg	6:51 PM EST		
Respectfully Submitted to the Committee,				
				
James P. Hancovsky, M.S.I.A., R.Ph. Chief Pharmacy Officer, UHC C&S				